VolitionRx Limited (NYSE AMERICAN: VNRX) announced the pricing of its public offering of 2,960,000 shares of common stock and warrants to purchase up to 1,480,000 shares at a combined price of $1.55 per share and accompanying half warrant.

The epigenetics company expects gross proceeds of approximately $4.6 million before deducting placement agent fees and other offering expenses. Each warrant carries an exercise price of $1.55 per share, becomes exercisable immediately upon issuance, and expires five years after issuance. If all warrants are exercised on a cash basis, the company could receive an additional $2.3 million in gross proceeds.

Maxim Group LLC serves as the sole placement agent for the offering. The transaction includes participation from both new and existing investors and is expected to close on June 9, 2026, subject to customary closing conditions.

The securities are being offered under an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission. The registration statement was initially filed on November 8, 2024, and declared effective on April 18, 2025.

VolitionRx develops blood tests for detecting and monitoring diseases including cancers and conditions associated with NETosis such as sepsis. The company operates research and development facilities in Belgium, with additional offices in the U.S. and London.